1. Home
  2. TEO vs DFTX Comparison

TEO vs DFTX Comparison

Compare TEO & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Telecom Argentina SA

TEO

Telecom Argentina SA

HOLD

Current Price

$13.08

Market Cap

5.4B

ML Signal

HOLD

Logo Definium Therapeutics Inc. Common Shares

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$44.04

Market Cap

5.9B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
TEO
DFTX
Founded
1979
N/A
Country
Argentina
United States
Employees
27818
106
Industry
Telecommunications Equipment
Sector
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
5.9B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TEO
DFTX
Price
$13.08
$44.04
Analyst Decision
Hold
Strong Buy
Analyst Count
2
8
Target Price
$12.30
$38.50
AVG Volume (30 Days)
726.8K
4.7M
Earning Date
05-11-2026
05-04-2026
Dividend Yield
2.19%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4.91
N/A
Revenue Next Year
$1.58
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.43
$14.62
52 Week High
$16.34
$49.20

Technical Indicators

Market Signals
Indicator
TEO
DFTX
Relative Strength Index (RSI) 48.33 75.74
Support Level $13.07 $17.51
Resistance Level $13.50 N/A
Average True Range (ATR) 0.64 2.86
MACD -0.18 1.10
Stochastic Oscillator 21.90 79.93

Price Performance

Historical Comparison
TEO
DFTX

About TEO Telecom Argentina SA

Telecom Argentina SA offers its customers quadruple play services, combining mobile telephony services, cable television services, Internet services and fixed telephony services. It also provides other telephone-related services such as international long-distance and wholesale services, data transmission and IT solutions outsourcing and install, operate and develop cable television and data transmission services. The company operates in segments: ICT Services provided in Argentina: Personal Network; ICT Services provided in Argentina - TMA Network; and Other segments..

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Share on Social Networks: